Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 2011. The document serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding changes in beneficial interests in the company's ordinary shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is strictly a regulatory disclosure of a specific share transaction and does not contain financial performance data.
Material Changes
The only material change disclosed is a transaction involving Mr. S M Bicknell, who acquired a beneficial interest in 10 Ordinary shares. This acquisition resulted from the re-investment of dividends under a Personal Equity Plan on January 6, 2011, at a price of £12.51 per share.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risks, contingencies, or unusual items. It is a compliance notification pursuant to Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Points
- Verify the identity of Mr. S M Bicknell as a director or person discharging managerial responsibility.
- Confirm the transaction date of January 6, 2011, and the notification date of January 7, 2011.
- Note that the share price for this specific transaction was £12.51 per share.
- Understand that this filing does not reflect broader company financial performance.